We are pleased to welcome Dr. Vivien Weber to strengthen our 4D Lifetec team. Vivien joins our diagnostic laboratory group in introducing the 4D Lifetest™ Lung Dx into our customers' routine diagnostics.
In addition to the ongoing launch of its products in Europe, 4D Lifetec has now started planing to enter the markets in the USA and China.
Cham, 13.01.2022 Are you interested to become a key member of our 4D Lifetec team and work cross-functionally to drive clinical execution and market introduction of the 4D Lifetec portfolio? Interested? Contact us today!
Cham, 10.01.2022 - Would you like to become an important part of our dynamic and motivated team? If you or anyone you know is interested in this role and wants to learn more, check out the posting or contact us directly. (Zur deutschen Version geht's hier).
After reporting the CE-IVD mark reception of our 4D Lifetest™ Lung Dx, 4D Lifetest™ Breast Dx and 4D Lifetest™ Colon Dx earlier this year we have now succeeded to also receive CE-IVD mark for our fourth cancer applications 4D Lifetest™ Prostate Dx.
In October we received the CE-IVD mark for our third diagnostic cancer assay
4D Lifetest™ Colon Dx.
In April we received the CE-IVD mark for the 4D Lifetest™ Lung Dx. Today we are happy to inform that our second application 4D Lifetest™ Breast Dx also received CE-IVD mark.
Please read the article on the startupticker.ch platform from 05.03.2021.
After positive results from our clinical validation studies in lung and prostate cancer in the past months, we have now also been able to successfully complete the breast cancer cohort.
The Swiss Biotech Association has listed our latest news.
Please read the article in the DeciBio Weekly Liquid Biopsy Digest from 21.01.2021
Please read the article in GenomeWeb from 05.01.2021
We are very pleased to announce that we have signed a cooperation agreement with VolitionRX to validate a completely novel concept for the use of liquid biopsies in cancer diagnostics.
In an observational study 'Prospective Evaluation of 4D LifetestTM Parameters to Develop a Universal Early Cancer Diagnosis Test', blood samples from 39 participants were collected (49% patients with newly diagnosed, untreated lung cancer and 51% non-cancer). Evaluation of our DDS biomarker (DNA Damage Sensitivity) comparing non-cancer with cancer samples resulted in more than 90% sensitivity at 95% specificity (95% CI: 76.4-99.7%) across all stages.
4D Lifetec filed a new patent to make the powerful cancer biomarker DDS part of its proprietary technology.
Preliminary results of the clinical study on the diagnosis of lung cancer patients show 4D Lifetest™ having a competitive or better sensitivity and specificity compared to leading diagnostic biomarkers for lung cancer. This is really another important breakthrough on the way to an effective multi-cancer assay.
We congratulate the entire team of the company for reaching this extremely important milestone.
With many exciting discussions at the JPM conference in San Francisco, 4D Lifetec has started to focus on the USA market entry.
We are very pleased that we were able to close the year 2019 with positive results. The results confirms our conviction that the 4D LifetestTM will soon reach the next important milestone.
After reaching Proof of Technology in August the 4D Lifetec team is exited to announce the successful reach of the next milestone by entering into the clinical study with the 4D Lifetest™.
As a awarded winner 4D Lifetec became part of the Venture Leaders Life Science Group 2019 and was invited to travel to Boston (USA).
Arne Faisst, our CEO, tells more about our plans in the US
Please vote for 4D Lifetec.
4D Lifetec AG has started the early cancer diagnostic validation program for its integral liquid biopsy assay 4D Lifetest™.
4D Lifetec has been recognized and selected out of approximately 200 applications for the W.A. de Vigier Start-up Award.
After some intense months the prototype phase for the 4D Lifetank has been completed by the end of 2016.
Are you interested in reading 4D Lifetec News from the beginning until 2017 please ask us for further information.
